BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 24970933)

  • 1. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
    Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
    Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
    Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
    Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
    Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
    Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
    Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
    Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
    Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
    Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
    Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts.
    Seo JY; Lee KO; Kim SH; Kim K; Jung CW; Jang JH; Kim HJ
    Ann Hematol; 2014 Apr; 93(4):603-8. PubMed ID: 24141330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1.
    Ok CY; Trowell KT; Parker KG; Moser K; Weinberg OK; Rogers HJ; Reichard KK; George TI; Hsi ED; Bueso-Ramos CE; Tam W; Orazi A; Bagg A; Arber DA; Hasserjian RP; Wang SA
    Mod Pathol; 2021 Jan; 34(1):20-31. PubMed ID: 32694616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory anemia with ring sideroblasts.
    Malcovati L; Cazzola M
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):377-85. PubMed ID: 24507814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Patnaik MM; Lasho TL
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications.
    Malcovati L; Ambaglio I; Elena C
    Curr Opin Oncol; 2015 Nov; 27(6):551-9. PubMed ID: 26352542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
    Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
    Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
    Faria C; Tzankov A
    Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
    Malcovati L; Cazzola M
    Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.